PMID- 26659222
OWN - NLM
STAT- MEDLINE
DCOM- 20161007
LR  - 20220316
IS  - 1549-490X (Electronic)
IS  - 1083-7159 (Print)
IS  - 1083-7159 (Linking)
VI  - 21
IP  - 1
DP  - 2016 Jan
TI  - High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization 
      Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients 
      Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing 
      Locally Advanced Breast Cancer.
PG  - 21-7
LID - 10.1634/theoncologist.2015-0101 [doi]
AB  - BACKGROUND: The present study was performed to determine whether the human 
      epidermal growth factor receptor-related 2 (HER2)/centromeric probe for 
      chromosome 17 fluorescence in situ hybridization (FISH) ratio is a predictor of a 
      pathologic complete response (pCR), recurrence-free survival (RFS), and/or 
      overall survival (OS) in patients receiving neoadjuvant systemic treatment (NST) 
      with trastuzumab (NST-T) for HER2+ locally advanced breast cancer (LABC). 
      PATIENTS AND METHODS: The present retrospective study included 555 patients with 
      HER2+ LABC who had undergone NST and definitive surgery (1999-2012); 373 had 
      concurrently received trastuzumab. HER2-positivity was considered present with an 
      immunohistochemical score of 3+ and/or HER2 FISH ratio of >/=2.0. We used logistic 
      regression analysis and Cox proportional hazard modeling to determine whether a 
      high HER2 FISH ratio, either as a continuous variable or with a cutoff of >/=7.0, 
      would predict for pCR (no invasive disease in the breast and no tumor in the 
      ipsilateral axillary lymph nodes), RFS, and/or OS. RESULTS: The pCR group's 
      median HER2 FISH ratio was significantly higher than that of the non-pCR group 
      (6.4 vs. 5.2; p = .003). The logistic regression model demonstrated that the 
      independent predictors of pCR included a high HER2 FISH ratio as a continuous 
      variable (p = .04). The multicovariate Cox proportional hazard model showed that 
      a high HER2 FISH ratio (with a cutoff of >/=7.0 or as a continuous variable) was a 
      significant prognostic indicator of longer RFS time (p = .047 and p = .04, 
      respectively). Similarly, a high HER2 FISH ratio of >/=7.0 was associated with 
      longer OS (p = .06). CONCLUSION: A high HER2 FISH ratio is a predictor of pCR in 
      patients with HER2+ LABC who receive NST-T. IMPLICATIONS FOR PRACTICE: This study 
      demonstrated the optimal predictive and prognostic value of a HER2/centromeric 
      probe for chromosome 17 FISH ratio for primary HER2+ breast cancer treated with 
      trastuzumab combined with neoadjuvant systemic treatment (NST-T). This suggests 
      that a high HER2 FISH ratio is a potential indicator for a high pathologic 
      complete response rate and a better prognosis when patients are treated with 
      NST-T.
CI  - (c)AlphaMed Press.
FAU - Kogawa, Takahiro
AU  - Kogawa T
AD  - Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The 
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of 
      Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas, USA.
FAU - Fouad, Tamer M
AU  - Fouad TM
AD  - Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The 
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of 
      Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas, USA.
FAU - Liu, Diane D
AU  - Liu DD
AD  - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas, USA.
FAU - Wu, Jimin
AU  - Wu J
AD  - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas, USA.
FAU - Shen, Yu
AU  - Shen Y
AD  - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas, USA.
FAU - Masuda, Hiroko
AU  - Masuda H
AD  - Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The 
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of 
      Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas, USA.
FAU - Fujii, Takeo
AU  - Fujii T
AD  - Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The 
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of 
      Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas, USA.
FAU - Chavez-MacGregor, Mariana
AU  - Chavez-MacGregor M
AD  - Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The 
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of 
      Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas, USA.
FAU - Alvarez, Ricardo H
AU  - Alvarez RH
AD  - Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The 
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of 
      Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas, USA.
FAU - Hortobagyi, Gabriel N
AU  - Hortobagyi GN
AD  - Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, Texas, USA.
FAU - Valero, Vicente
AU  - Valero V
AD  - Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The 
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of 
      Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas, USA.
FAU - Ueno, Naoto T
AU  - Ueno NT
AD  - Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The 
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of 
      Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas, USA nueno@mdanderson.org.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151209
PL  - England
TA  - Oncologist
JT  - The oncologist
JID - 9607837
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & dosage
MH  - Breast Neoplasms/*drug therapy/*genetics/pathology
MH  - Centromere/*genetics
MH  - Chromosomes, Human, Pair 17
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - *Neoadjuvant Therapy
MH  - Paclitaxel/administration & dosage
MH  - Prognosis
MH  - Receptor, ErbB-2/*biosynthesis/genetics
MH  - Retrospective Studies
MH  - Trastuzumab/administration & dosage
PMC - PMC4709200
OTO - NOTNLM
OT  - HER2+ breast cancer
OT  - HER2/centromeric probe for chromosome 17 fluorescence in situ hybridization ratio
OT  - Pathologic complete response
OT  - Predictive factor
OT  - Trastuzumab
COIS- Disclosures of potential conflicts of interest may be found at the end of this 
      article.
EDAT- 2015/12/15 06:00
MHDA- 2016/10/08 06:00
PMCR- 2017/01/01
CRDT- 2015/12/15 06:00
PHST- 2015/09/17 00:00 [received]
PHST- 2015/09/21 00:00 [accepted]
PHST- 2015/12/15 06:00 [entrez]
PHST- 2015/12/15 06:00 [pubmed]
PHST- 2016/10/08 06:00 [medline]
PHST- 2017/01/01 00:00 [pmc-release]
AID - theoncologist.2015-0101 [pii]
AID - T15101 [pii]
AID - 10.1634/theoncologist.2015-0101 [doi]
PST - ppublish
SO  - Oncologist. 2016 Jan;21(1):21-7. doi: 10.1634/theoncologist.2015-0101. Epub 2015 
      Dec 9.